Navamedic (NAVA)

TekBot · desember 29, 2025, 7:24am

Grete Roede og Navamedic lanserer nytt vektreduksjonskonsept: Lettere steg

Grete Roede og Navamedic inngår et samarbeid om en ny, strukturert metode for
vektreduksjon. Det første konseptet, Lettere steg, lanseres i romjulen 2025 og
fortsetter inn i 2026. Konseptet legger vekt på fellesskap, støtte og
…

Vis børsmeldingen

erfaringsdeling underveis i prosessen.

Hele Norges «slankedronning» Grete Roede grunnla selskapet for å hjelpe nordmenn
med å få kontroll over vekten. I dag ledes selskapet av datteren Jeanette Roede
og tilbyr personlig veiledning, kurs og digitale løsninger gjennom blant annet
Grete Roede-appen.

I Grete Roede har vi alltid vært opptatt av forskningsbaserte og bærekraftige
metoder for vektreduksjon, kombinert med god og tett oppfølging. Sammen med
Navamedic kompletterer vi nå vårt eksisterende tilbud med et nytt alternativ,
som gir flere en trygg og strukturert start på vektreduksjon, sier Jeanette
Roede, daglig leder i Grete Roede.

Ernæring med dokumentert effekt

Navamedic har en bred portefølje av reseptfrie og reseptpliktige produkter,
blant annet innen fedme. De står også bak Modifast, en produktserie kost- og
måltidserstatninger med dokumentert effekt på vektreduksjon. Produktene brukes i
dag både i kliniske settinger og av forbrukere, og er utviklet for å gi
fullverdig ernæring innenfor et strukturert kostholdsprogram.

Gjennom samarbeidet med Grete Roede blir produktene nå i konseptet Lettere Steg
en integrert del av et helhetlig veiledningsløp, tilgjengelig via Grete Roedes
landsdekkende nettverk av sertifiserte veiledere og digitale flater.

Mange som ønsker å gå ned i vekt mangler nettopp struktur og støtte i
oppstartsfasen. Lettere steg kombinerer et tydelig rammeverk med personlig
oppfølging og fellesskap, noe vi vet er avgjørende for å lykkes over tid, sier
Karianne Femtehjell Olsen, Commercial Director i Navamedic.

Et svar på en økende folkehelseutfordring

Overvekt og fedme er blant de største folkehelseutfordringene i Norge. Ifølge
Folkehelseinstituttet har om lag én av fire voksne fedme, og andelen er økende.

Tall fra Nordisk monitorering (NORMO 2025) viser at vi både spiser for mye og
for dårlig, samtidig som vi beveger oss for lite. Utviklingen går i retning av
dårligere kostvaner og økende overvekt.

Gjennom Lettere steg ønsker vi å støtte flere i å ta grep i hverdagen, etablere
sunnere vaner og forbedre egen helse. Samtidig peker Fedmerapporten 2025 på at
mange mangler nødvendig støtte og oppfølging for å lykkes med varig
vektreduksjon¹.

Med dette samarbeidet ønsker vi å bidra til at flere får tilgang til trygge,
tilgjengelige og individuelt tilpassede løsninger som faktisk fungerer i
hverdagen, sier Jeanette Roede.

Lettere steg - en strukturert og støttende start

Det første prosjektet i samarbeidet er Lettere steg, et 12-ukers program som
kombinerer dokumenterte ernæringsprodukter fra Modifast med tett personlig
oppfølging fra sertifiserte Roede-veiledere.

Lettere steg er utviklet for personer som ønsker en tydelig, motiverende og
gjennomførbar start på en varig livsstilsendring. Fellesskap, støtte og
erfaringsdeling er sentrale elementer i konseptet

Les mer www.letteresteg.no

Videre utvikling

Lettere steg lanseres i romjulen 2025, og samarbeidet mellom Grete Roede og
Navamedic vil videreutvikles gjennom 2026.

Om Navamedic ASA

Navamedic ASA er et nordisk farmasøytisk selskap med ambisjon om å forbedre
folks livskvalitet gjennom levering av reseptbelagte legemidler,
forbrukerhelseprodukter og spesialernæring av høy kvalitet til apotek og
sykehus. Selskapet har en voksende produktportefølje rettet mot sentrale
folkehelseutfordringer, med særlig fokus på overvekt.

Kontaktperson:
Karianne Femtehjell Olsen, Commercial Director
E-post: kfo@navamedic.com

Om Grete Roede AS

Grete Roede AS er en ledende aktør innen livsstilsveiledning og vektreduksjon i
Norge. Med over 50 års erfaring har selskapet hjulpet tusenvis av mennesker til
en sunnere og mer balansert livsstil gjennom personlig veiledning, kurs og
digitale tjenester.

Kontaktperson:
Jeanette Roede, daglig leder
E-post: jeanette.roede@roede.com

Fedmerapporten 2025, Navamedic.

Kilde

TekBot · januar 7, 2026, 11:47am

https://www.finansavisen.no/tema/morten_jurs

Navamedic ASA: Minutes of Extraordinary General Meeting

Oslo, 7 January 2026: The announced extraordinary general meeting of Navamedic ASA (“Navamedic” or the “Company”, OSE ticker: “NAVA”) was held today at 12:00 CET. All items on the agenda were approved in accordance with the board of directors’ proposals and the nomination committee’s recommendations. A copy of the minutes from the extraordinary general meeting is attached to this notice and will also be made available on the Company’s webpage www.navamedic.com.

This information is subject to the disclosure requirements in section 5-12 of the Norwegian Securities Trading Act.
…

Vis børsmeldingen

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Mobile: +47 951 78 880, e-mail: kathrine@navamedic.com
Nils Ole Krekling, CFO, Mobile: +47 924 24 016, e-mail: nils.ole.krekling@navamedic.com

About Navamedic
Navamedic ASA is a full-service provider of high-quality healthcare products to hospitals and pharmacies. Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit www.navamedic.com.

Kilde

Savepig · januar 7, 2026, 11:48am

TekBot · januar 19, 2026, 1:02pm

Financial calendar

TekBot · februar 9, 2026, 8:20am

Navamedic ASA: Invitation to presentation of fourth quarter 2025 results

Navamedic ASA will present its fourth quarter 2025 results on Thursday, 12 February 2026 at 08:30 CET at Haakon VIIs gate 2, Oslo, Norway.

The presentation will also be streamed live and available on demand via the following link: https://navamedic.com/investors.
…

Vis børsmeldingen

About Navamedic
Navamedic ASA is a full-service provider of high-quality healthcare products to hospitals and pharmacies. Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit www.navamedic.com.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · februar 12, 2026, 6:00am

Navamedic ASA: Strong growth and important product launch in Q4 2025

Oslo, 12 February 2026 - In the fourth quarter of 2025, Navamedic ASA achieved
its highest quarterly revenue ever at NOK 157.1 million, a 19.8 per cent growth
compared to same period last year. This reflects a full quarter with revenues
…

Vis børsmeldingen

from the Addiction portfolio that was acquired on 15 July 2025. For the full
year, Navamedic reported revenues of NOK 565.4 million, marking a 6.4 per cent
increase over 2024. Adjusted EBITDA for the quarter amounted to NOK 13.4
million, while the full-year adjusted EBITDA came in at NOK 47.6 million.

“We have completed a good fourth quarter with strong growth both as a result of
the acquisition that we completed in July and an increase in demand for our
products within antibiotics. We continue working on improving our gross margins,
and I am pleased to see that we have achieved above 40 per cent in the quarter,”
says Kathrine Gamborg Andreassen, CEO of Navamedic.

The growth in the fourth quarter was driven by the addition of the acquired
Addiction portfolio as well as a significant increase in sale of antibiotics to
Nordic hospitals after recent tender wins during 2025. This translated into a
growth for Prescription Drugs of 24.1 per cent in the quarter, and a growth for
Hospital of 40.3 per cent in the quarter compared to the same quarter last year.
Consumer Health saw a 6.6 per cent reduction in revenues in the fourth quarter
compared to same quarter last year mainly due to periodization of campaign
activities.

The growth for full-year 2025 of 6.4 per cent was largely due to strong growth
within antibiotics and the impact from the acquired Addiction portfolio. The
resulting growth in Hospital was 22.9 per cent in 2025, while Prescription Drugs
and Consumer Health grew at 10.5 per cent and 2.3 per cent respectively.

Gross margin came in at 40.3 per cent in the quarter, a significant improvement
from the result in the same period last year of 33.7 per cent. The full-year
gross margin in 2025 was on par with last year at 39.0 per cent.

“We have managed to grow the company in 2025 without any large out-licensing
milestones, and in a market for obesity products that has continued to be very
competitive. With the full-year effect of the addiction portfolio and some
growth in other product areas, I believe we should be able to continue a similar
growth path in 2026. We will also work hard to stabilize our gross margins above
40 per cent,” says Kathrine Gamborg Andreassen.

“The launch in December 2025 of Flexilev in OraFID for advanced Parkinson’s care
reflects our commitment to be a proud contributor to public health and was an
important milestone in our growth plan, but the volume for this product will
still be modest in 2026,” says Kathrine Gamborg Andreassen.

Presentation and webcast

CEO Kathrine Gamborg Andreassen and CFO Nils Ole Krekling will present the
results today at 08:30 CET at Haakon VIIs gate 2, Oslo, Norway. The presentation
will be streamed live and available on demand via the following link:
Investors - Navamedic

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, mobile: +47 951 78 680
Nils Ole Krekling, CFO, mobile: +47 924 24 016

About Navamedic
Navamedic ASA is a full-service provider of high-quality healthcare products to
hospitals and pharmacies. Navamedic meets the specific medical needs of patients
and consumers by leveraging its highly scalable market access platform, leading
category competence and local knowledge. Navamedic is present in all the Nordic
countries, the Baltics and Benelux, with sales representation in Greece.
Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange (ticker: NAVA). For more information, please visit www.navamedic.com.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · februar 12, 2026, 6:00am

Navamedic ASA: Sterk vekst og viktig produktlansering i fjerde kvartal 2025

Oslo, 12. februar 2026 - Navamedic ASAs omsetning i fjerde kvartal 2025 var
157,1 millioner kroner. Dette er det beste kvartalet hittil, og 19,8 prosent
høyere enn samme periode i fjor. Dette inkluderer et helt kvartal med inntekter
…

Vis børsmeldingen

fra Addiction-porteføljen, hvor oppkjøpet ble fullført 15. juli 2025. Inntektene
for hele året var på 565,4 millioner kroner, en økning på 6,4 prosent fra 2024.
Justert EBITDA for kvartalet endte på 13,4 millioner kroner, mens justert EBITDA
for hele året var 47,6 millioner kroner.

«Vi har levert et godt fjerde kvartal med sterk vekst, både som følge av
oppkjøpet vi fullførte i juli og økt etterspørsel etter våre
antibiotikaprodukter. Vi fortsetter å jobbe med å forbedre vår bruttomargin, og
jeg er fornøyd med at vi har oppnådd over 40 prosent i kvartalet,» sier Kathrine
Gamborg Andreassen, CEO i Navamedic.

Veksten i fjerde kvartal skyldes i stor grad den oppkjøpte Addiction-porteføljen
samt en betydelig økning i salget av antibiotika til nordiske sykehus etter
anbudskonkurranser i 2025. Dette resulterte i en vekst for Prescription Drugs på
24,1 prosent i kvartalet, og en vekst for Hospital på 40,3 prosent sammenlignet
med samme kvartal i fjor. Consumer Health hadde en nedgang i inntektene på 6,6
prosent i fjerde kvartal sammenlignet med samme kvartal i fjor, primært grunnet
periodisering av markedskampanjer.

Veksten for hele 2025 på 6,4 prosent drives i stor grad av sterk vekst innen
antibiotika og den oppkjøpte Addiction-porteføljen. Veksten for Hospital var
22,9 prosent i 2025, mens Prescription Drugs og Consumer Health vokste med
henholdsvis 10,5 prosent og 2,3 prosent.

Bruttomarginen endte på 40,3 prosent i kvartalet, en betydelig forbedring fra
marginen i samme periode i fjor på 33,7 prosent. Bruttomarginen for hele 2025
var på nivå med fjoråret på 39,0 prosent.

«Vi har klart å vokse selskapet i 2025 uten store milepæler for ut-lisensiering,
og i et marked for fedmeprodukter som fortsatt er preget av sterk konkurranse.
Med helårseffekt fra Addiction-porteføljen og noe vekst innen andre
produktområder, mener jeg vi bør kunne levere lignende vekst i 2026. Vi vil også
jobbe hardt for å stabilisere bruttomarginen over 40 prosent,» sier Kathrine
Gamborg Andreassen.

«Lanseringen i desember 2025 av Flexilev i OraFID for avansert Parkinson
-behandling viser vårt engasjement for å være en stolt bidragsyter til
folkehelsen og var en viktig milepæl i vår vekstplan. Volumet for dette
produktet vil imidlertid fortsatt være beskjedent i 2026,» sier Kathrine Gamborg
Andreassen.

Presentasjon og webcast

CEO Kathrine Gamborg Andreassen og CFO Nils Ole Krekling presenterer resultatene
i dag kl. 08.30 i Haakon VIIs gate 2, Oslo. Presentasjonen strømmes direkte og
vil være tilgjengelig som opptak via følgende lenke:
Investors - Navamedic

For ytterligere informasjon, vennligst kontakt:

Kathrine Gamborg Andreassen, CEO, mobil: +47 951 78 680
Nils Ole Krekling, CFO, mobil: +47 924 24 016

Om Navamedic
Navamedic ASA er en fullserviceleverandør av høykvalitets helseprodukter til
sykehus og apotek. Navamedic dekker pasienters og forbrukeres medisinske behov
ved å utnytte sin skalerbare plattform for markedsadgang, ledende
kategorikompetanse og lokal kunnskap. Navamedic er til stede i alle de nordiske
landene, Baltikum og Benelux, og har salgsrepresentasjon i Hellas. Selskapet har
hovedkontor i Oslo, og er notert på Oslo Børs (ticker: NAVA). For mer
informasjon, besøk www.navamedic.com.

Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12.

Kilde

Quadruple · februar 13, 2026, 9:34am

Det blir spennende å se om Jurs som styreformann vil utgjøre en forskjell inneværende år.

https://snl.no/Morten_Jurs

TekBot · februar 27, 2026, 12:05pm

Navamedic ASA: Mandatory notification of trade

TekBot · februar 27, 2026, 1:30pm

Flaggemelding Navamedic ASA

TekBot · februar 27, 2026, 1:40pm

Flaggemelding NAVA

TekBot · mars 25, 2026, 12:12pm

Annual Report 2025

TekBot · mars 31, 2026, 10:00am

Navamedic ASA: Notice of Annual General Meeting

The annual general meeting of Navamedic ASA will be held on Thursday, 23 April 2026 at 15:00 (CEST) at the company’s offices at Henrik Ibsens gate 100, 0255 Oslo. Shareholders may also participate digitally or cast votes in advance.

The notice of the meeting, including the agenda as well as the notice of attendance, advance voting and proxy form, is attached to this message and is also available, together with the related attachments, at General Meeting - Navamedic.
…

Vis børsmeldingen

About Navamedic
Navamedic ASA is a full-service provider of high-quality healthcare products to hospitals and pharmacies. Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit www.navamedic.com.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Kilde

Savepig · april 9, 2026, 8:16am

Må helst finne støtte snart denne, eller så er det dypt nedover

Quadruple · april 10, 2026, 9:26am

Quadruple · april 10, 2026, 3:27pm

Positioned for Growth in Promising Healthcare Segments

Navamedic ASA (”Navamedic” or ”the Company”) is a Nordic pharmaceutical company offering a diversified portfolio of prescription drugs, consumer health products, and hospital solutions in the Nordic region, the Baltics, and the Benelux region. Following a strategic shift in 2019, transitioning from a distribution-based model to owning brands, Navamedic has enhanced profitability and scalability. The Company’s licensing platform, enabling control over product portfolios and facilitating market expansion, positions Navamedic for sustained growth going forward. Navamedic is estimated to reach an EBIT of NOK 71.1m in 2026 and based on an applied EV/EBIT target multiple of 10.4x, a potential price per share of NOK 37.5 is implied in a Base scenario.

Quadruple · april 13, 2026, 8:10am

Upside remains strong

We have revised our estimates for interest-bearing debt and lowered our revenue and margin assumptions, resulting in net negative estimate revisions. Nonetheless, we see no change in the company’s underlying fundamentals or the long-term investment case at this time. We continue to see strong growth potential in the current strategy, supported by multiple levers: growth from the existing product base, out-licensing of proprietary products to capture opportunities beyond the company’s core markets through distributors and partners, in-licensing of products and brands, and acquisitions of smaller companies and product portfolios with growth potential. This includes opportunities related to Flexilev in OraFID®, as well as within antibiotics, addiction, and other therapeutic areas. The main risk, in our view, is execution. As the company expands into new markets, uncertainty remains around product stickiness and the pace of the sales ramp-up. That said, the company’s broad product portfolio and limited reliance on any single growth driver make the strategy well balanced and supportive of long-term growth. We reiterate our BUY recommendation and maintain our TP of NOK 28/sh., implying upside of roughly 40% from the current share price. (Norne Rersearch)

TekBot · april 15, 2026, 3:23pm

Navamedic ASA: Recommendation of the nomination committee for the Annual General Meeting on 23 April 2026

Oslo, 15 April 2026: Reference is made to the stock exchange announcement by Navamedic ASA published on 31 March 2026, regarding the company’s annual general meeting being held on 23 April 2026. The nomination committee’s recommendation was not available at the time the notice was distributed but has now been submitted to the annual general meeting.

The nomination committee has nominated the following persons to members of the company’s board of directors:
…

Vis børsmeldingen

Candidate 1: Morten Jurs nominated as chairperson

Candidate 2: Rune Wahl nominated as board member

Candidate 3: Hilde Furberg nominated as board member

Candidate 4: Camilla Harder Hartvig nominated as board member

Candidate 5: Mads Helmich Pedersen nominated as board member

Candidate 6: Otto Moltke-Hansen nominated as board observer

Candidate 7: position is intentionally left vacant

In addition, the nomination committee has nominated the following persons as members of the company’s nomination committee:

Candidate 1: Bård Brath Ingerø nominated as leader

Candidate 2: Katarina Hammar nominated as member

Candidate 3: Karianne Melleby nominated as member

The nomination committee’s recommendation, including inter alia, information on proposed remuneration to members of the board of directors, the various board committees and the nomination committee is attached hereto and will be made available on the company’s website General Meeting - Navamedic.

At the annual general meeting, the shareholders will vote on the candidates on an individual basis in accordance with the Norwegian Code of Practice for Corporate Governance (NUES). Votes and proxies already submitted will remain valid, and there is no need to vote again or submit a new proxy as a result of this announcement.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · april 20, 2026, 6:33am

Navamedic ASA: Invitation to presentation of first quarter 2026 results

Navamedic ASA will present its first quarter 2026 results on Thursday, 23 April 2026 at 08:30 CEST at Haakon VIIs gate 2, Oslo, Norway.

The presentation will also be streamed live and available on demand via the following link: https://navamedic.com/investors.
…

Vis børsmeldingen

About Navamedic
Navamedic ASA is a full-service provider of high-quality healthcare products to hospitals and pharmacies. Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit www.navamedic.com.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Kilde

Savepig · april 20, 2026, 6:58am

Interessant rykk i denne før helgen